Liver Targeting of Daclatasvir via Tailoring Sterically Stabilized Bilosomes: Fabrication, Comparative In Vitro/In Vivo Appraisal and Biodistribution Studies

References

• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infection. 2011;17(2):107–115. doi:10.1111/j.1469-0691.2010.03432.x
   PubMed Web of Science ®Google Scholar
• Zaman B, Siddique F, Hassan W. RP-HPLC method for simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form and its application to in vitro dissolution studies. Chromatographia. 2016;79(23–24):1605–1613. doi:10.1007/s10337-016-3179-9
   Google Scholar
• Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. Daclatasvir: a review of preclinical and clinical pharmacokinetics. Clin Pharmacokinet. 2018;57(8):911–928. doi:10.1007/s40262-017-0624-3
   PubMed Web of Science ®Google Scholar
• Jagadabi V, Nagendra Kumar P, Mahesh K, Pamidi S, Ramaprasad L, Nagaraju D. A stability-indicating UPLC method for the determination of potential impurities and its mass by a new QDa mass detector in daclatasvir drug used to treat hepatitis C infection. J Chromatogr Sci. 2019;57(1):44–53. doi:10.1093/chromsci/bmy079
   PubMedGoogle Scholar
• Böttger R, Pauli G, Chao P-H, Al-Fayez N, Hohenwarter L, Li S-D. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev. 2020;154–155:79–101.
   PubMedGoogle Scholar
• El-Kharrag R, Amin A, Greish YE. Low temperature synthesis of monolithic mesoporous magnetite nanoparticles. Ceramics Int. 2012;38(1):627–634. doi:10.1016/j.ceramint.2011.07.052
   Google Scholar
• Rabanel M, Aoun V, Elkin I, Mokhtar M, Hildgen P. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. Curr Med Chem. 2012;19(19):3070–3102. doi:10.2174/092986712800784702
   PubMed Web of Science ®Google Scholar
• Liu J, Li M, Luo Z, Dai L, Guo X, Cai K. Design of nanocarriers based on complex biological barriers in vivo for tumor therapy. Nano Today. 2017;15:56–90. doi:10.1016/j.nantod.2017.06.010
   Web of Science ®Google Scholar
• Hu S, Niu M, Hu F, et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm. 2013;441(1–2):693–700. doi:10.1016/j.ijpharm.2012.10.025
   PubMed Web of Science ®Google Scholar
• He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W. Adapting liposomes for oral drug delivery. Acta pharmaceutica sinica B. 2019;9(1):36–48. doi:10.1016/j.apsb.2018.06.005
   PubMed Web of Science ®Google Scholar
• Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2016;23(6):1847–1867.
   PubMed Web of Science ®Google Scholar
• Xue W, Trital A, Shen J, Wang L, Chen S. Zwitterionic polypeptide-based nanodrug augments pH-triggered tumor targeting via prolonging circulation time and accelerating cellular internalization. ACS Appl Mater Interfaces. 2020;12(41):46639–46652. doi:10.1021/acsami.0c11747
   PubMed Web of Science ®Google Scholar
• Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A. Size, shape, charge and “stealthy” surface: carrier properties affect the drug circulation time in vivo. Asian J Pharmaceutical Sci. 2020. doi:10.1016/j.ajps.2020.07.005
   PubMedGoogle Scholar
• Zheng L, Sundaram HS, Wei Z, Li C, Yuan Z. Applications of zwitterionic polymers. React Funct Polym. 2017;118:51–61. doi:10.1016/j.reactfunctpolym.2017.07.006
   Web of Science ®Google Scholar
• Kapoor M, Howard R, Hall I, Appleton I. Effects of epicatechin gallate on wound healing and scar formation in a full thickness incisional wound healing model in rats. Am J Pathol. 2004;165(1):299–307. doi:10.1016/S0002-9440(10)63297-X
   PubMedGoogle Scholar
• Elkomy MH, El Menshawe SF, Abou-Taleb HA, Elkarmalawy MH. Loratadine bioavailability via buccal transferosomal gel: formulation, statistical optimization, in vitro/in vivo characterization, and pharmacokinetics in human volunteers. Drug Deliv. 2017;24(1):781–791. doi:10.1080/10717544.2017.1321061
   PubMed Web of Science ®Google Scholar
• El-Nabarawi MA, Shamma RN, Farouk F, Nasralla SM. Bilosomes as a novel carrier for the cutaneous delivery for dapsone as a potential treatment of acne: preparation, characterization and in vivo skin deposition assay. J Liposome Res. 2020;30(1):1–11. doi:10.1080/08982104.2019.1577256
   PubMed Web of Science ®Google Scholar
• Abdelbary AA, Abd-Elsalam WH, Al-mahallawi AM. Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: in vitro characterization, ex vivo permeation and in vivo safety assessment. Int J Pharm. 2016;513(1–2):688–696. doi:10.1016/j.ijpharm.2016.10.006
   PubMed Web of Science ®Google Scholar
• Al-mahallawi AM, Abdelbary AA, Aburahma MH. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam. Int J Pharm. 2015;485(1–2):329–340. doi:10.1016/j.ijpharm.2015.03.033
   PubMed Web of Science ®Google Scholar
• Albash R, El-Nabarawi MA, Refai H, Abdelbary AA. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Int J Nanomedicine. 2019;14:6555. doi:10.2147/IJN.S213613
   PubMed Web of Science ®Google Scholar
• US FDA Center for Drug Evaluation and Research. Generic drugs division of bioequivalence. FDA Recommended Dissolution Methods. 2016.
   Google Scholar
• Naik S, Patel D, Surti N, Misra A. Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J Supercrit Fluids. 2010;54(1):110–119. doi:10.1016/j.supflu.2010.02.005
   Web of Science ®Google Scholar
• Soni K, Rizwanullah M, Kohli K. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments. Artif Cells, Nanomed Biotechnol. 2018;46(sup1):15–31. doi:10.1080/21691401.2017.1408124
   PubMed Web of Science ®Google Scholar
• Parashar P, Rana P, Dwivedi M, Saraf SA. Dextrose modified bilosomes for peroral delivery: improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats. J Liposome Res. 2019;29(3):251–263. doi:10.1080/08982104.2018.1551408
   PubMed Web of Science ®Google Scholar
• Vukelic S, Stojadinovic O, Pastar I, et al. Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor. J Biol Chem. 2010;285(3):1980–1988. doi:10.1074/jbc.M109.016741
   PubMedGoogle Scholar
• Aboud HM, Ali AA, El-Menshawe SF, Elbary AA. Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation. Drug Deliv. 2016;23(7):2471–2481. doi:10.3109/10717544.2015.1013587
   PubMed Web of Science ®Google Scholar
• Rao TS, Sridevi M, Naidu CG, Nagaraju B. Ionic liquid-based vortex-assisted DLLME followed by RP-LC-PDA method for bioassay of daclatasvir in rat serum: application to pharmacokinetics. J Analytical Sci Tech. 2019;10(1):20. doi:10.1186/s40543-019-0179-z
   Google Scholar
• Nasr M, Ghorab MK, Abdelazem A. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting. Acta pharmaceutica sinica B. 2015;5(1):79–88. doi:10.1016/j.apsb.2014.12.001
   PubMed Web of Science ®Google Scholar
• Abdallah OM, Abdel‐Megied AM, Gouda AS. Development and validation of LC‐MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: application to pharmacokinetic study. Biomed Chromatography. 2018;32(6):e4186. doi:10.1002/bmc.4186
   PubMedGoogle Scholar
• Dodiya S, Chavhan S, Korde A, Sawant KK. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Dev Ind Pharm. 2013;39(5):733–743. doi:10.3109/03639045.2012.694889
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306–314. doi:10.1016/j.cmpb.2010.01.007
   PubMed Web of Science ®Google Scholar
• Lai L, Guo H. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm. 2011;404(1–2):317–323. doi:10.1016/j.ijpharm.2010.11.025
   PubMedGoogle Scholar
• Moolakkadath T, Aqil M, Ahad A, et al. Preparation and optimization of fisetin loaded glycerol based soft nanovesicles by Box-Behnken design. Int J Pharm. 2020;578:119125. doi:10.1016/j.ijpharm.2020.119125
   PubMed Web of Science ®Google Scholar
• Vardhan MV, Sankaraiah G, Yohan M, Rao HJ. Optimization of Parameters in CNC milling of P20 steel using Response Surface methodology and Taguchi Method. Materials Today. 2017;4(8):9163–9169.
   Google Scholar
• El-Marakby EM, Hathout RM, Taha I, Mansour S, Mortada ND. A novel serum-stable liver targeted cytotoxic system using valerate-conjugated chitosan nanoparticles surface decorated with glycyrrhizin. Int J Pharm. 2017;525(1):123–138. doi:10.1016/j.ijpharm.2017.03.081
   PubMed Web of Science ®Google Scholar
• Shah N, Gohil D, Seth A. Nanostructured Lipid Carriers. Efficient Drug Delivery Carrier. 2017;2:548.
   Google Scholar
• Guan P, Lu Y, Qi J, Wu W. Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. Colloids Surf B Biointerfaces. 2016;144:143–151. doi:10.1016/j.colsurfb.2016.04.006
   PubMed Web of Science ®Google Scholar
• Ahad A, Raish M, Ahmad A, Al-Jenoobi FI, Al-Mohizea AM. Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmaceutical Sci. 2018;111:409–417. doi:10.1016/j.ejps.2017.10.012
   PubMed Web of Science ®Google Scholar
• de Freitas CF, Calori IR, Tessaro AL, Caetano W, Hioka N. Rapid formation of Small Unilamellar Vesicles (SUV) through low-frequency sonication: an innovative approach. Colloids Surf B Biointerfaces. 2019;181:837–844. doi:10.1016/j.colsurfb.2019.06.027
   PubMedGoogle Scholar
• El-Say KM, Abd-Allah FI, Lila AE, Hassan AE-SA, Kassem AEA. Diacerein niosomal gel for topical delivery: development, in vitro and in vivo assessment. J Liposome Res. 2016;26(1):57–68. doi:10.3109/08982104.2015.1029495
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Y, Chen J, et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm. 2009;376(1–2):153–160. doi:10.1016/j.ijpharm.2009.04.022
   PubMed Web of Science ®Google Scholar
• Khalil RM, Abdelbary A, Kocova El-Arini S, Basha M, El-Hashemy HA. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. J Liposome Res. 2019;29(2):171–182. doi:10.1080/08982104.2018.1524482
   PubMed Web of Science ®Google Scholar
• Matloub AA, Salama AH, Aglan HA, AbouSamra MM, ElSouda SSM, Ahmed HH. Exploiting bilosomes for delivering bioactive polysaccharide isolated from Enteromorpha intestinalis for hacking hepatocellular carcinoma. Drug Dev Ind Pharm. 2018;44(4):523–534. doi:10.1080/03639045.2017.1402922
   PubMed Web of Science ®Google Scholar
• Allam AF. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Devel Ther. 2016;10:2421–2433. doi:10.2147/DDDT.S113775
   PubMed Web of Science ®Google Scholar
• Mohsen AM, Asfour MH, Salama AA. Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes. Drug Dev Ind Pharm. 2017;43(12):2043–2054. doi:10.1080/03639045.2017.1361968
   PubMed Web of Science ®Google Scholar
• Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAps Pharmscitech. 2010;11(3):1119–1127. doi:10.1208/s12249-010-9480-2
   PubMed Web of Science ®Google Scholar
• Khelashvilia G, Johnera N, Zhaob G, Harries D, Scott HL. Molecular origins of bending rigidity in lipids with isolated and conjugated double bonds: the effect of cholesterol. Chem Phys Lipids. 2014;178:18–26. doi:10.1016/j.chemphyslip.2013.12.012
   PubMedGoogle Scholar
• Ayee MA, Levitan I. Paradoxical impact of cholesterol on lipid packing and cell stiffness. Front Biosci. 2016;21:1245–1259. doi:10.2741/4454
   Google Scholar
• Harbi I, Aljaeid B, Khalid M, Zidan AS. Glycosylated sertraline-loaded liposomes for brain targeting: qbD study of formulation variabilities and brain transport. AAPS PharmSciTech. 2016;17(6):1404–1420. doi:10.1208/s12249-016-0481-7
   PubMed Web of Science ®Google Scholar
• El-Helw A-RM, Fahmy UA. Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. Int J Nanomedicine. 2015;10:5797. doi:10.2147/IJN.S91556
   PubMed Web of Science ®Google Scholar
• Detampel P, Witzigmann D, Krähenbühl S, Huwyler J. Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes. J Drug Target. 2014;22(3):232–241. doi:10.3109/1061186X.2013.860982
   PubMed Web of Science ®Google Scholar
• Shehata T, Kimura T, Higaki K. In-vivo disposition characteristics of PEG niosome and its interaction with serum proteins. Int J Pharm. 2016;512(1):322–328. doi:10.1016/j.ijpharm.2016.08.058
   PubMedGoogle Scholar
• Davarpanah F, Yazdi AK, Barani M, Mirzaei M, Torkzadeh-Mahani M. Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes. DARU J Pharmaceutical Sci. 2018;26(1):57–64. doi:10.1007/s40199-018-0215-3
   Google Scholar
• Tsermentseli SK, Kontogiannopoulos KN, Papageorgiou VP, Assimopoulou AN. Comparative study of PEGylated and conventional liposomes as carriers for shikonin. Fluids. 2018;3(2):36. doi:10.3390/fluids3020036
   Google Scholar
• Zeisig R, Shimada K, Hirota S, Arndt D. Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines. Biochimica et Biophysica Acta. 1996;1285(2):237–245. doi:10.1016/S0005-2736(96)00167-8
   PubMedGoogle Scholar
• Abdelbary AA, Abd-Elsalam WH, Al-Mahallawi AM. Fabrication of levofloxacin polyethylene glycol decorated nanoliposomes for enhanced management of acute otitis media: statistical optimization, trans-tympanic permeation and in vivo evaluation. Int J Pharm. 2019;559:201–209. doi:10.1016/j.ijpharm.2019.01.037
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials. 2011;32(28):6791–6803. doi:10.1016/j.biomaterials.2011.04.082
   PubMed Web of Science ®Google Scholar
• Panwar P, Pandey B, Lakhera P, Singh K. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine. 2010;5:101.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han L, Sun X, Gao D, Qin J, Wang J. The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia. 2012;83(4):678–689. doi:10.1016/j.fitote.2012.02.004
   PubMed Web of Science ®Google Scholar
• Ramana LN, Sharma S, Sethuraman S, Ranga U, Krishnan UM. Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. Int J Pharm. 2012;431(1–2):120–129. doi:10.1016/j.ijpharm.2012.04.054
   PubMed Web of Science ®Google Scholar
• Li T, Chen L, Deng Y, et al. Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, in vitro, and in vivo characterization. Drug Dev Ind Pharm. 2017;43(12):2016–2025. doi:10.1080/03639045.2017.1361965
   PubMed Web of Science ®Google Scholar
• Guo B, Cheng Y, Li N, et al. In vitro and in vivo studies of galactose-modified liver-targeting liposomes. J Drug Target. 2013;21(3):257–264. doi:10.3109/1061186X.2012.741135
   PubMed Web of Science ®Google Scholar
• Gupta P, Hung C. Quantitative evaluation of targeted drug delivery systems. Int J Pharm. 1989;56(3):217–226. doi:10.1016/0378-5173(89)90018-5
   Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283–318.
   PubMed Web of Science ®Google Scholar